Results with Optilume consistent in clinical trials and real world, regardless of prostate ...

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...

Modern medical research shows that drug and surgical treatments for benign prostatic hyperplasia and chronic prostatitis carry high risks, while Dr Allen's Device, developed by Fine Treatment, an ...

Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...

One such change, often less spoken about, is the enlargement of the prostate gland. This condition, known as Benign Prostatic Hyperplasia (BPH), is extremely common, especially in men above 50 years ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

The Urocross® Expander System is designed to remodel the obstructing prostatic lobes during the six-month indwell time and is ...

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia: Sunnyvale, California Thu ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...

Straining when going to the toilet is a classic symptom of constipation, and usually occurs when stools are too hard to easily pass.

A prescription medication that has been available in the U.S. since 1992 might have another significant benefit.

HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant ...